ReceptoPharm  
Home   Drug Development   CRO Services   Newsroom   About ReceptoPharm   Contact
» Overview
» Research Platform
» R&D Pipeline
» Published Research
» Licensing
 
Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More
 
CRO Services

ReceptoPharm offers a full range of contract research services catering to small and start-up biotech companies.

» Learn More

R&D Pipeline

ReceptoPharm's research and development pipeline consists of several novel therapies in various stages of development to prevent and/or treat Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN), Herpes, Rheumatoid Arthritis (RA) and Pain.

 
Planning
 
 
In Progress
 
 
Completed
 

Abbreviations
Preclinical (PC), Phase 1 (P-I), Phase 2 (P-II), Phase 3 (P-III)

RPI-78M

 
Indication
PC
P-I
P-II
P-III
       
  Herpes Simplex Infections 1 & 2      
         
     

RPI-MN

 
Indication
PC
P-I
P-II
P-III
         
 
Human Immunodeficiency Virus
   
 

Amyotrophic Lateral Sclerosis

       
  Herpes Simplex Keratitis        

RPI-78

 
Indication
PC
P-I
P-II
P-III
         
     

Cobroxin

 
Indication
Regulatory Status
 
Chronic Pain (Over-the-Counter)
Marketing

 
Cobroxin for Chronic Pain
Cobroxin is the first over-the-counter pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis. For more information, visit http://www.Cobroxin.com.
Recent News
February 02, 2010
Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin
 
E-Alerts
Signup to receive news and announcements from ReceptoPharm and Nutra Pharma:
First Name:
Last Name:
Email:
NPC